<DOC>
<DOCNO>EP-0624590</DOCNO> 
<TEXT>
<INVENTION-TITLE>
N-acylated staurosporine derivatives, process and intermediates for their preparation and their use as medicaments.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K3155	A61K3155	A61P900	A61P910	A61P1700	A61P1700	A61P3500	A61P3500	A61P4300	A61P4300	C07D20700	C07D20704	C07D27300	C07D27306	C07D30900	C07D30912	C07D31100	C07D31122	C07D49800	C07D49822	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P17	A61P17	A61P35	A61P35	A61P43	A61P43	C07D207	C07D207	C07D273	C07D273	C07D309	C07D309	C07D311	C07D311	C07D498	C07D498	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
There are described N-(tetrahydropyran-4-yloxyalkanoyl)staurosporin derivatives of the formula I 
<
IMAGE
>
 in which R1 is hydrogen, hydroxyl, lower alkoxy or oxo, R2 is hydrogen or C1-4-alkyl and R3 is hydrogen or C1-4-alkyl, a process and novel intermediates for their preparation and a process for the preparation of the intermediates. The compounds of the formula I inhibit the enzyme protein kinase C with a high degree of selectivity and can be used, in particular, as antitumour active compounds.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CIBA GEIGY AG
</APPLICANT-NAME>
<APPLICANT-NAME>
CIBA-GEIGY AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
WACKER OSKAR DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WACKER, OSKAR, DR.
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
